Print

Print


------------------------------------------------------------------------
Dose response to intraventricular glial cell line-derived neurotrophic
factor [GDNF] administration in parkinsonian monkeys.
------------------------------------------------------------------------

A double-blinded study was conducted to evaluate the dose response of
hemiparkinsonian rhesus monkeys to intracerebroventricular (ICV) injections
of recombinant methionine human glial cell line-derived neurotrophic factor
(GDNF).

Thirty rhesus monkeys with stable hemiparkinsonian features were divided
into six treatment groups (vehicle, 10, 30, 100, 300 and 1000 microg GDNF;
n = 5/group). Each animal received 4 ICV administrations spaced at four
week intervals. In addition, the animals were followed for 4 mo after the
last injection.

Standardized video taped behavioral tests were used to rate parkinsonian
features using a nonhuman primate rating scale and assess side effects from
treatment.

Significant behavioral improvements were measured in animals receiving 100
to 1000 microg GDNF.

One month after the last GDNF administration, parkinsonian features in
animals receiving 100 and 1000 microg GDNF began to return to baseline
levels.

However, 300 microg GDNF recipients continued to display behavioral
improvements.

Parkinsonian features significantly improved were: bradykinesia, rigidity,
posture and balance.

The most common side effect was a transient weight loss after GDNF
administration.

Only one other side effect was observed, one animal receiving 1000 microg
GDNF displayed dyskinetic movements.

The results provide additional information for evaluating the possible
clinical application of GDNF for treating Parkinson's disease.


J Pharmacol Exp Ther 1997 Sep;282(3):1396-1401
Zhang Z, Miyoshi Y, Lapchak PA, Collins F,
Hilt D, Lebel C, Kryscio R, Gash DM
University of Kentucky Medical Center, Lexington, Kentucky 40536-0084, USA.
PMID: 9316852, MUID: 97461171
----------------------------------------------------------------------------

[log in to unmask]